Nuclear SMAD2 restrains proliferation of glioblastoma

Cellular Physiology and Biochemistry

Volumn 35, Issue 5, 2015, Pages 1756-1763

  Yu, Yunhu ^a   Ran, Qishan ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer cell growth; Glioblastoma multiforme (GBM); p21; SMAD2; SMAD3; Transforming growth factor (TGF )

Indexed keywords

PROTEIN P27; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; RECOMBINANT PROTEIN; SMAD2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BRAIN TISSUE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GLIOBLASTOMA; HUMANS; PHOSPHORYLATION; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84926163715     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373987     Document Type: Article

References (49)

1. Schonberg DL, Bao S, Rich JN: Genomics informs glioblastoma biology. Nat Genet 2013;45:1105-1107.
2. Chen J, Huang Q, Wang F: Inhibition of foxo1 nuclear exclusion prevents metastasis of glioblastoma. Tumour Biol 2014;35:7195-7200.
3. Gong J, Zhu S, Zhang Y, Wang J: Interplay of vegfa and mmp2 regulates invasion of glioblastoma. Tumour Biol 2014;35:11879-11885.
4. Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, Liu Y: Egfr signaling-dependent inhibition of glioblastoma growth by ginsenoside rh2. Tumour Biol 2014;35:5593-5598.
5. Wang F, Xiao W, Sun J, Han D, Zhu Y: Mirna-181c inhibits egfr-signaling-dependent mmp9 activation via suppressing akt phosphorylation in glioblastoma. Tumour Biol 2014;35:8653-8658.
6. Massague J: Tgfbeta in cancer. Cell 2008;134:215-230.
7. Shi Y, Massague J: Mechanisms of tgf-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
8. Kretzschmar M, Massague J: Smads: Mediators and regulators of tgf-beta signaling. Curr Opin Genet Dev 1998;8:103-111.
9. Massague J, Chen YG: Controlling tgf-beta signaling. Genes Dev 2000;14:627-644.
10. Massague J: Tgfbeta signalling in context. Nat Rev Mol Cell Biol 2012;13:616-630.
11. Xiao X, Wiersch J, El-Gohary Y, Guo P, Prasadan K, Paredes J, Welsh C, Shiota C, Gittes GK: Tgfbeta receptor signaling is essential for inflammation-induced but not beta-cell workload-induced beta-cell proliferation. Diabetes 2013;62:1217-1226.
12. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, Song Z, El-Gohary Y, Prasadan K, Shiota C, Gittes GK: M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A 2014;111:E1211-1220.
13. Liu R, Zhou Z, Huang J, Chen C: Pmepa1 promotes androgen receptor-negative prostate cell proliferation through suppressing the smad3/4-c-myc-p21 cip1 signaling pathway. J Pathol 2011;223:683-694.
14. Chuang TD, Guh JY, Chiou SJ, Chen HC, Hung WC, Chuang LY: Sp1 and smad3 are required for high glucoseinduced p21(waf1) gene transcription in llc-pk1 cells. J Cell Biochem 2007;102:1190-1201.
15. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M, Sharma DK, Pagano RE, Leof EB: Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of smad2 and smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005;65:10431-10440.
16. Charng MJ, Wu CH: Transcriptional activation of p21 by tranilast is mediated via transforming growth factor beta signal pathway. Br J Pharmacol 2006;147:117-124.
17. Pardali K, Kowanetz M, Heldin CH, Moustakas A: Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(waf1/cip1). J Cell Physiol 2005;204:260-272.
18. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A: Role of smad proteins and transcription factor sp1 in p21(waf1/cip1) regulation by transforming growth factor-beta. J Biol Chem 2000;275:29244-29256.
19. Miles FL, Tung NS, Aguiar AA, Kurtoglu S, Sikes RA: Increased tgf-beta1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with smad2/3 signaling. Prostate 2012;72:1339-1350.
20. Lecanda J, Ganapathy V, D'Aquino-Ardalan C, Evans B, Cadacio C, Ayala A, Gold LI: Tgfbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest. Cell Cycle 2009;8:742-756.
21. Baughn LB, Di Liberto M, Niesvizky R, Cho HJ, Jayabalan D, Lane J, Liu F, Chen-Kiang S: Cdk2 phosphorylation of smad2 disrupts tgf-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J Immunol 2009;182:1810-1817.
22. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, Cuartas I, Raventos C, Martinez-Ricarte F, Poca MA, Garcia-Dorado D, Lahn MM, Yingling JM, Rodon J, Sahuquillo J, Baselga J, Seoane J: Tgf-beta receptor inhibitors target the cd44(high)/id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010;18:655-668.
23. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J: Tgf-beta increases glioma-initiating cell self-renewal through the induction of lif in human glioblastoma. Cancer Cell 2009;15:315-327.
24. Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, Weller M, Unsicker K: Expression and putative functions of gdf-15, a member of the tgf-beta superfamily, in human glioma and glioblastoma cell lines. Cancer Lett 2008;270:30-39.
25. Grzmil M, Morin P, Jr., Lino MM, Merlo A, Frank S, Wang Y, Moncayo G, Hemmings BA: Map kinaseinteracting kinase 1 regulates smad2-dependent tgf-beta signaling pathway in human glioblastoma. Cancer Res 2011;71:2392-2402.
26. Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE: Blockade of tgf-beta signaling by the tgfbetar-i kinase inhibitor ly2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155-7167.
27. Piek E, Westermark U, Kastemar M, Heldin CH, van Zoelen EJ, Nister M, Ten Dijke P: Expression of transforming-growth-factor (tgf)-beta receptors and smad proteins in glioblastoma cell lines with distinct responses to tgf-beta1. Int J Cancer 1999;80:756-763.
28. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, Garcia-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J: Usp15 stabilizes tgfbeta receptor i and promotes oncogenesis through the activation of tgf-beta signaling in glioblastoma. Nat Med 2012;18:429-435.
29. Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M: Differential regulation of tgf-beta-induced, alk-5-mediated vegf release by smad2/3 versus smad1/5/8 signaling in glioblastoma. Neuro Oncol 2015;17:254-265.
30. Golestaneh N, Mishra B: Tgf-beta, neuronal stem cells and glioblastoma. Oncogene 2005;24:5722-5730.
31. Pen A, Moreno MJ, Durocher Y, Deb-Rinker P, Stanimirovic DB: Glioblastoma-secreted factors induce igfbp7 and angiogenesis by modulating smad-2-dependent tgf-beta signaling. Oncogene 2008;27:6834-6844.
32. Joseph JV, Conroy S, Tomar T, Eggens-Meijer E, Bhat K, Copray S, Walenkamp AM, Boddeke E, Balasubramanyian V, Wagemakers M, den Dunnen WF, Kruyt FA: Tgf-beta is an inducer of zeb1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dise 2014;5:e1443.
33. Lv S, Zhang J, Han M, Wang W, Zhang Y, Zhuang D, Shi R, Bian R, Yao C: Nucleolin promotes tgf-beta signaling initiation via tgf-beta receptor i in glioblastoma. J Mol Neurosci 2015;55:1-6.
34. Jiang H, Jin C, Liu J, Hua D, Zhou F, Lou X, Zhao N, Lan Q, Huang Q, Yoon JG, Zheng S, Lin B: Next generation sequencing analysis of mirnas: Mir-127-3p inhibits glioblastoma proliferation and activates tgf-beta signaling by targeting ski. OMICS 2014;18:196-206.
35. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, Franciszkiewicz K, Chouaib S, Kaminska B: Microglia-derived tgf-beta as an important regulator of glioblastoma invasion-an inhibition of tgf-beta-dependent effects by shrna against human tgf-beta type ii receptor. Oncogene 2008;27:918-930.
36. Pan JJ, Chang WJ, Barone TA, Plunkett RJ, Ostrow PT, Greenberg SJ: Increased expression of tgf-beta1 reduces tumor growth of human u-87 glioblastoma cells in vivo. Cancer Immunol Immunother 2006;55:918-927.
37. Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, Weller M, Platten M: Processing of immunosuppressive pro-tgf-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 2001;166:7238-7243.
38. Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA: Retroviral-mediated transduction of p53 gene increases tgf-beta expression in a human glioblastoma cell line. Int J Cancer 1994;56:834-839.
39. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-1423.
40. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, Lee H, Merriman B, Nelson SF: U87mg decoded: The genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 2010;6:e1000832.
41. Ganzinger M, He S, Breuhahn K, Knaup P: On the ontology based representation of cell lines. PLoS One 2012;7:e48584.
42. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ: Identification of novel inhibitors of the transforming growth factor beta1 (tgf-beta1) type 1 receptor (alk5). J Med Chem 2002;45:999-1001.
43. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: Sb-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type i activin receptor-like kinase (alk) receptors alk4, alk5, and alk7. Mol Pharmacol 2002;62:65-74.
44. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA: Inhibition of transforming growth factor (tgf)-beta1-induced extracellular matrix with a novel inhibitor of the tgf-beta type i receptor kinase activity: Sb-431542. Mol Pharmacol 2002;62:58-64.
45. Huang S, Liao Q, Li L, Xin D: Pttg1 inhibits smad3 in prostate cancer cells to promote their proliferation. Tumour Biol 2014;35:6265-6270.
46. Yu X, Jiang Y, Wei W, Cong P, Ding Y, Xiang L, Wu K: Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour Biol 2014.
47. Kfir S, Ehrlich M, Goldshmid A, Liu X, Kloog Y, Henis YI: Pathway-and expression level-dependent effects of oncogenic n-ras: P27(kip1) mislocalization by the ral-gef pathway and erk-mediated interference with smad signaling. Mol Cell Biol 2005;25:8239-8250.
48. Birchenall-Roberts MC, Fu T, Bang OS, Dambach M, Resau JH, Sadowski CL, Bertolette DC, Lee HJ, Kim SJ, Ruscetti FW: Tuberous sclerosis complex 2 gene product interacts with human smad proteins. A molecular link of two tumor suppressor pathways. J Biol Chem 2004;279:25605-25613.
49. Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA, Lodish HF, Henis YI: Disruption of tgf-beta growth inhibition by oncogenic ras is linked to p27kip1 mislocalization. Oncogene 2000;19:5926-5935.